Cerevel Therapeutics (CERE) News Today → Biden replacement revealed? (From Paradigm Press) (Ad) Free CERE Stock Alerts $42.59 -0.04 (-0.09%) (As of 10:04 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAddex stock tanks after lead drug flops in Phase II epilepsy trialfinance.yahoo.com - April 30 at 8:49 AMTop 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talksfinance.yahoo.com - April 26 at 9:04 PMHold Rating Maintained for Cerevel Post-Positive Phase 3 Data Amid Pending AbbVie Acquisitionmarkets.businessinsider.com - April 22 at 1:05 PMCalamos Advisors LLC Makes New Investment in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)marketbeat.com - April 20 at 7:43 AMSoon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Studybenzinga.com - April 18 at 2:31 PMAbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drugmsn.com - April 18 at 8:20 AMCerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage studyreuters.com - April 18 at 8:20 AMCerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Diseasefinance.yahoo.com - April 18 at 8:20 AMCerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Diseaseglobenewswire.com - April 18 at 6:30 AMAnalysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)markets.businessinsider.com - April 16 at 3:54 PMCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Short Interest Up 38.2% in Marchmarketbeat.com - April 12 at 8:36 PMAbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%seekingalpha.com - April 12 at 2:27 PMInternational Assets Investment Management LLC Takes Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)marketbeat.com - April 11 at 5:21 AMCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Receives Average Rating of "Hold" from Brokeragesmarketbeat.com - April 9 at 2:15 AMCerevel Therapeutics director sells $2.12m in stock, buys $175k worthinvesting.com - April 5 at 5:43 AMDirector N Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings Inc (CERE)uk.finance.yahoo.com - April 3 at 11:04 PMVanguard Group Inc. Purchases 708,826 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)marketbeat.com - April 3 at 4:09 AM24,487 Shares in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Acquired by SG Americas Securities LLCmarketbeat.com - March 31 at 4:16 AMCerevel Therapeutics Holdings Inc.wsj.com - March 29 at 8:39 AMAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS)markets.businessinsider.com - March 29 at 8:39 AMAssenagon Asset Management S.A. Invests $12.72 Million in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)marketbeat.com - March 29 at 5:16 AMHudson Bay Capital Management LP Invests $1.09 Million in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)marketbeat.com - March 17 at 5:12 AMN Anthony Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Stockinsidertrades.com - March 16 at 8:17 AMCERE Apr 2024 40.000 callfinance.yahoo.com - March 16 at 2:48 AMGraham Capital Management L.P. Raises Stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)marketbeat.com - March 15 at 5:22 AMCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Sold by Polar Capital Holdings Plcmarketbeat.com - March 13 at 8:12 AMCantor Fitzgerald Research Analysts Lower Earnings Estimates for Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)marketbeat.com - March 11 at 1:29 AMCerevel Therapeutics: Hold Rating Amidst Pending AbbVie Acquisitionmarkets.businessinsider.com - March 7 at 7:06 AMAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Perspective Therapeutics (CATX)markets.businessinsider.com - March 6 at 4:05 PMCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Bought by Adage Capital Partners GP L.L.C.marketbeat.com - March 6 at 8:18 AMCerevel Therapeutics: Parkinson's Could Be The Issueseekingalpha.com - March 6 at 7:20 AMLake Street Advisors Group LLC Acquires New Shares in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)marketbeat.com - March 5 at 3:14 PMCharles Schwab Investment Management Inc. Has $11.29 Million Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)marketbeat.com - February 29 at 4:26 AMMaintaining Hold Rating Amid ABBV-CERE Deal Progress and Rising Operational Costsmarkets.businessinsider.com - February 28 at 2:01 PMWestfield Capital Management Co. LP Boosts Stock Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)marketbeat.com - February 28 at 8:12 AMCitigroup Inc. Increases Stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)marketbeat.com - February 25 at 4:49 AMABBV Mar 2024 182.500 calluk.finance.yahoo.com - February 24 at 3:32 PMUS Politicians Raise Concerns Over Capital One-Discover Dealbloomberg.com - February 23 at 11:35 PM3M Healthcare Unit Solventum Joins $53 Billion US Corporate Bond Sales Spreeuk.finance.yahoo.com - February 23 at 1:34 PMAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Intra-Cellular Therapies (ITCI)markets.businessinsider.com - February 22 at 8:53 PMAbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevelfinance.yahoo.com - February 22 at 3:53 PMAbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reportsreuters.com - February 21 at 11:21 PMAbbVie (ABBV) Announces Appointment of New CEO Robert Michaelfinance.yahoo.com - February 21 at 1:21 PMCerevel Therapeutics (NASDAQ:CERE) Sees Unusually-High Trading Volumemarketbeat.com - February 20 at 11:56 AMFmr LLC Increases Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)marketbeat.com - February 20 at 7:30 AMWall Street Breakfast Podcast: OpenAI's Text-To-Video AI Modelseekingalpha.com - February 16 at 8:39 PMCerevel Therapeutics (NASDAQ:CERE) Price Target Raised to $45.00marketbeat.com - February 16 at 7:39 PMAnalysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Bio-Rad Laboratories (BIO)markets.businessinsider.com - February 16 at 10:38 AMCerevel Therapeutics (NASDAQ:CERE) Sets New 52-Week High at $43.59marketbeat.com - February 15 at 10:45 AMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Roivant Sciences (ROIV)markets.businessinsider.com - February 14 at 3:27 PM Get Cerevel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter. Email Address The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet. See how you can invest alongside him CERE Media Mentions By Week CERE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CERE News Sentiment▼0.370.33▲Average Medical News Sentiment CERE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CERE Articles This Week▼33▲CERE Articles Average Week Get Cerevel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Legend Biotech News Today Ascendis Pharma A/S News Today Jazz Pharmaceuticals News Today Intra-Cellular Therapies News Today Viking Therapeutics News Today Roivant Sciences News Today Elanco Animal Health News Today Cytokinetics News Today Ionis Pharmaceuticals News Today Blueprint Medicines News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CERE) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportYour bank is lying to you.MyBankTrackerDollar CancelledLear CapitalUrgent Alert: Is the U.S. Implementing a Digital Dollar?Gold Gate Capital Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
